Abstract: Oxide-based thin film sintered bodies, oxide-based solid electrolyte sheets, and all-solid lithium secondary batteries are disclosed. In some implementations, an oxide-based thin film sintered body includes oxide particles, the oxide-based thin film sintered body having a surface roughness Ra ranging from 0.1 to 3 ?m, wherein Ra is an arithmetical mean height of a surface, wherein the oxide particles absorb light energy in a wavelength range from 10 to 1200 nm and have an energy band gap ranging from 0.1 to 15 eV.

Abstract: A driver assistance system for vehicles, which is capable of preventing driver carelessness from causing a vehicle accident when a vehicle stops while traveling, includes a vehicle sensor unit configured to detect driver state data, a driver assistance unit operated to assist a driver when driver carelessness about vehicle driving is detected when a vehicle stops while traveling, and a control unit configured to identify whether the driver is careless based on the driver state data when the vehicle stops while traveling, and to operate the driver assistance unit when the driver carelessness is detected, preventing the vehicle from driving.

Abstract: An oxide-based film sheet according to an embodiment of the disclosure includes an oxide-based particle, wherein the oxide-based particle includes a colored oxide particle capable of absorbing light energy in a visible light spectrum. An oxide-based solid electrolyte sheet according to an embodiment of the disclosure may be prepared by light-sintering the oxide-based film sheet. According to an embodiment of the disclosure, an oxide-based solid electrolyte sheet in which a connection structure between particles, shapes of the particles, porosity, or the like are appropriately provided may be prepared by light-sintering.

Abstract: The present disclosure relates to a method for producing novel glia-like cells that are differentiated from somatic cells and secrete 20,000 pg/ml or more of Hepatocyte growth factor (HGF), 150 pg/ml or more of Brain-derived neurotrophic factor (BDNF), and 10 ng/ml or more of Macrophage migration inhibitory factor (MIF), using a chemical cocktail composition for producing the same.

Abstract: The present invention relates to a method for direct reprogramming from somatic cells into pancreatic beta cells by using microRNA and small-molecule materials. The inventors of the present invention confirmed that, as a result of having attempted direct reprogramming upon co-treatment of microRNA and small-molecules (e.g., various differentiation-inducing materials), the expression level of PDX1 remarkably increased in pancreatic beta cells, and, when pancreatic beta-like cells were induced using such a method, direct reprogramming was performed with very high yield. In addition, since autologous cells are used, the present invention has the advantages of no occurrence of immune rejection responses and a low possibility of developing cancer, and thus is expected to be effectively used in the development of safer cellular therapeutic agents.

Abstract: The present disclosure relates to a method for producing exosomes through electrical stimulation. More particularly, the present disclosure relates to a method for producing exosomes, the method including: (a) applying radio frequency (RF) electrical stimulation to cells and culturing the cells; and (b) isolating exosomes from the cells and a culture medium containing the cells.

Abstract: The present disclosure relates to novel glia-like cells that are differentiated from somatic cells and secrete 20,000 pg/ml or more of HGF, a chemical cocktail composition for producing the same, a method for producing the same, a cell therapy product for treating neurological disorder containing the same, and a method of preventing and treating neurological disorder by administering the same.

Abstract: The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.

Abstract: The present invention relates to an antimicrobial method of killing bacteria having a mannitol metabolic pathway by inhibition of a mannitol metabolism, a method of screening a mannitol metabolic inhibitor, and an antimicrobial composition and cosmetic material containing a mannitol metabolic inhibitor. More particularly, the present invention relates to an antimicrobial method targeted at mannitol dehydrogenase such as mannitol-1-phosphate-5-dehydrogenase (M1PDH), a method of screening an inhibitor, and a composition. Therefore, the antimicrobial method, antimicrobial composition, and cosmetic material which solve a problem of antibiotic resistance and have an excellent antimicrobial effect may be provided.

Abstract: Provided are a peptide for inhibiting an interaction between an RANKL and an RANK consisting of an amino acid sequence of SEQ ID NO: 1 and a pharmaceutical composition for preventing or treating bone diseases including the peptide. The peptide consisting of an amino acid sequence of SEQ ID NO: 1 is not present in a cyclic shape, and has 10 or less amino acids, thereby having better biostability than a conventional peptide to inhibit an RANKL-RANK interaction, being preferable in price during synthesis, and having a better RANKL-RANK interaction inhibitory effect. For this reason, the peptide may be used as an effective component of the composition effectively inhibiting differentiation of osteoclasts. A pharmaceutical composition including the peptide is bound with the RANKL and the peptide, instead of the RANK, thereby inhibiting the interaction between the RANKL and the RANK, and thus inhibiting osteoclast differentiation.

Abstract: Provided are a peptide for inhibiting an interaction between an RANKL and an RANK consisting of an amino acid sequence of SEQ ID NO: 1 and a pharmaceutical composition for preventing or treating bone diseases including the peptide. The peptide consisting of an amino acid sequence of SEQ ID NO: 1 is not present in a cyclic shape, and has 10 or less amino acids, thereby having better biostability than a conventional peptide to inhibit an RANKL-RANK interaction, being preferable in price during synthesis, and having a better RANKL-RANK interaction inhibitory effect. For this reason, the peptide may be used as an effective component of the composition effectively inhibiting differentiation of osteoclasts. A pharmaceutical composition including the peptide is bound with the RANKL and the peptide, instead of the RANK, thereby inhibiting the interaction between the RANKL and the RANK, and thus inhibiting osteoclast differentiation.

Abstract: The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.

Abstract: The present invention relates to a method for in vitro phosphorylation of TRAP derived from Staphylococcus aureus. In the present invention, the TRAP is first identified as a kinase that self-phosphorylates and is phosphorylated specifically in the presence of an oxidative metal ion such as iron, copper and zinc. Based upon this finding, a novel method for in vitro phosphorylation of purified TRAP is provided and also, a method for screening various chemicals and natural materials by using the above method is provided in order to select inhibitors against the TRAP phosphorylation. The inhibitors are expected to be applied for novel antibiotics of Staphylococcus aureus, because this TRAP phosphorylation is essential to infect Staphylococcus aureus. Therefore, the present invention can be widely used to develop novel drugs against Staphylococcus aureus and their resistant strains, in near future.

Abstract: The present invention relates to a method for in vitro phosphorylation of TRAP derived from Staphylococcus aureus. In the present invention, the TRAP is first identified as a kinase that self-phosphorylates and is phosphorylated specifically in the presence of an oxidative metal ion such as iron, copper and zinc. Based upon this finding, a novel method for in vitro phosphorylation of purified TRAP is provided and also, a method for screening various chemicals and natural materials by using the above method is provided in order to select inhibitors against the TRAP phosphorylation. The inhibitors are expected to be applied for novel antibiotics of Staphylococcus aureus, because this TRAP phosphorylation is essential to infect Staphylococcus aureus. Therefore, the present invention can be widely used to develop novel drugs against Staphylococcus aureus and their resistant strains, in near future.

Abstract: There are disclosed a crystal of complex of RRF with a detergent, its crystallization method and a method for identifying an inhibitor for RRF by using the three-dimensional structure of RRF analyzed from the crystal. In the present invention, a crystal of RRF complexed with a detergent is obtained in the presence of the detergent, and the three-dimensional structure of RRF is analyzed from the crystal. There are identified an active site forming hydrophobic cleft and binding site of RRF to A-site of ribosome in the three-dimensional structure of RRF. The three-dimensional structure of RRF, specifically, the active site and binding site can allow an inhibitor for RRF to be designed and identified efficiently. RRF is essential for viability in prokaryotes, but is not essential in eukaryotes. From this fact, the inhibitor for RRF can be used as an antibiotic.

Abstract: A crystal of E. coli RRF complexed with a detergent is disclosed as well as the three-dimensional structure of the complex as analyzed by X-ray diffraction. The crystallization method and a method for identifying an inhibitor of RRF based on the identified three-dimensional structure is also disclosed. The RRF crystal was obtained in the presence of a detergent, and the three-dimensional structure of RRF was analyzed from this crystal. The active site forming a hydrophobic cleft and the binding site of RRF to the A-site of the ribosome was identified in the three-dimensional structure of RRF. The three-dimensional structure of RRF, and particularly, the active site and binding site can aid in the identification or modeling of an inhibitor for RRF. Because RRF is essential for viability in prokaryotes, but is not essential in eukaryotes the inhibitor can be used as an antibiotic.